Oxcia is focusing the development of OXC-101 on hematological cancers
Following a strategy and data review, Oxcia has chosen to re-prioritize the clinical development of OXC-101 from solid tumors to hematological cancers, specifically acute myeloid leukemia (AML). The preclinical program for OXC-101 has shown good results in both AML and other forms of hematological cancers, and data to date from the phase I/II study MAATEO confirm the previous results. Oxcia has initiated an expansion part of the MAATEO study in patients with refractory/relapsed AML (R/R AML), where OXC-101 is administered in combination with idarubicin (an anthracycline).
- The first AML patient to be treated with OXC-101 in an innovative combination treatment has recently been recruited, which is very exciting, says Oxcia’s CEO Ulrika Warpman Berglund. We aim to accelerate patient recruitment, for instance by including more study centers in AML, e.g. Rigshospitalet in Copenhagen. We are also working on an ODD (Orphan Drug Designation) application.
Biostock has today published an article describing Oxcia's investment in AML and IPF, see Oxcias vd om satsningen på AML och lungfibros - BioStock (Oxcia's CEO on the investment in AML and pulmonary fibrosis - BioStock - only available in Swedish)
Until now, OXC-101 has also been evaluated in the MASTIFF study, a phase I/II study in severely ill patients with an expansion group focused on advanced ovarian cancer and prostate cancer. OXC-101 demonstrated a clear clinically relevant effect, halting cancer growth in a majority of patients. At the same time, some patients suffered dose-limiting side effects in the form of neutropenia.
- Neutropenia means a decrease in neutrophil granulocytes, a type of white blood cell that is important for the immune system. We are now conducting preclinical studies to better understand these mechanisms. Next, we will investigate which doses, indications and patient groups we could proceed with in solid tumors. However, the focus of Oxcia's development is on AML emphasizes CEO Ulrika Warpman Berglund.
For more information contact:
Ulrika Warpman Berglund, CEO, Oxcia AB (publ)
Telephone: +46 (0) 73 270 9605
ulrika.warpmanberglund@oxcia.com
Briefly about Oxcia
Oxcia AB is a pioneer in oxidative DNA damage and DNA Damage Response (DDR - the processes the body uses to repair the damage that occurs to DNA) with a focus on developing new safe treatments for patients suffering from diseases caused by cancer or inflammation. Oxcia currently has two DDR drug candidates, both with the potential to become first-in-class drugs. OXC-101 is in early clinical development as novel cancer therapy. OXC-201 is developed against inflammatory and fibrosis-related diseases, such as pulmonary fibrosis and allergic asthma, and is in the preclinical phase.
More information about Oxcia is available at www.oxcia.com